N+1 Singer Reaffirms Strong-Buy Rating for Verona Pharma (VRP)
Verona Pharma (LON:VRP)‘s stock had its “strong-buy” rating reiterated by investment analysts at N+1 Singer in a research report issued to clients and investors on Friday.
Other analysts also recently issued reports about the stock. reiterated a “buy” rating on shares of Verona Pharma in a report on Tuesday, November 7th. Jefferies Group reiterated a “buy” rating and issued a GBX 250 ($3.45) target price on shares of Verona Pharma in a report on Wednesday, November 8th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of GBX 130 ($1.80).
Shares of Verona Pharma (LON VRP) opened at GBX 145 ($2.00) on Friday. Verona Pharma has a fifty-two week low of GBX 100 ($1.38) and a fifty-two week high of GBX 189 ($2.61). The company has a market cap of $167.10 and a P/E ratio of -659.09.
About Verona Pharma
Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company’s product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound.
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.